Therapeutics Stocks Q1 Recap: Biogen and Peers Beat Revenue Estimates by 14.5%

StockStory··Read original
2▲4 ▼1Impact / 5
Summary · why it matters

The 11 therapeutics stocks tracked by StockStory reported a satisfactory first quarter, with aggregate revenues beating analysts' consensus estimates by 14.5%. Biogen posted revenues of $2.48 billion, up 1.9% year on year and exceeding expectations by 11.2%, while Moderna achieved the fastest revenue growth among peers with $389 million, up 260% and beating estimates by 55.8%. United Therapeutics delivered the weakest performance against analyst estimates, with revenues of $781.5 million down 1.6% and missing expectations by 1.9%. AbbVie reported $15 billion in revenues, up 12.4% and topping estimates by 1.7%, and Amgen posted $8.62 billion, up 5.8% and surpassing expectations by 1.4%. Share prices of the group have held steady, up 4.6% on average since the latest earnings results.

Impact on assets 5

Biotech & Genomic Medicine± Mixed · 5 stocks
Moderna Inc
MRNA
▲ PositiveCapitalrelevance

Moderna achieved fastest revenue growth among peers with $389M, up 260% and beating estimates by 55.8%.

Biogen Inc
BIIB
▲ PositiveCapitalrelevance

Biogen reported Q1 revenues of $2.48B, up 1.9% and exceeding expectations by 11.2%.

United Therapeutics Corporation
UTHR
▼ NegativeCapitalrelevance

United Therapeutics delivered weakest performance against estimates, with revenues of $781.5M down 1.6% and missing expectations by 1.9%.

AbbVie Inc
ABBV
▲ PositiveCapitalrelevance

AbbVie reported Q1 revenues of $15B, up 12.4% and beating estimates by 1.7%.

Amgen Inc
AMGN
▲ PositiveCapitalrelevance

Amgen posted Q1 revenues of $8.62B, up 5.8% and surpassing expectations by 1.4%.

© 2026 MarketIVNews